Novel agents, including anti-CD38 monoclonal antibodies (e.g., daratumumab), venetoclax for t(11;14) subsets, and CAR T-cell therapies, are being investigated for refractory PCL and offer hope for improved survival [60,61,62]. This evidence concerns the gene CD38 and plasma cell leukemia.